By Dr. Yuriy Abramov, Exe. Director of CC&DS, J-Star Research Regulatory expectations for control of impurities in new drugs have been established through ICH guidelines. The most efficient approach...
By Dr. Michal Achmatowicz, Mirati Therapeutics Abstract: A new approach to stereopure atropisomeric molecules is enabled by a continuous flow-crystallization process. Continuous accumulation of the product under its optimal...
Dr. Michal Achmatowicz received Ph.D. in organic chemistry in 2001 after working with Prof. Janusz Jurczak at the University of Warsaw and the Institute of Organic Chemistry of the...
By Drs. Yuriy Abramov and Shanming Kuang, Center for Pharma Crystallization, J-Star Research Small molecule drug candidates tend to have different solid forms, including anhydrate, hydrate, solvate, salt, cocrystal...
Dr. Yuriy Abramov is an industrial computational scientist with over 18 years experience at Pfizer Inc. Currently he holds a position of an Executive Director of computational chemistry and...
Dr. Nima Yazdanpanah is a consultant on advanced manufacturing and modeling and simulation applications in Bio/pharmaceutical and fine chemical industries. His area of expertise covers process simulation, particulate matters,...
By Dr. Nima Yazdanpanah, Consultant, Procegence Mechanistic modelling and process simulation, based on first-principle analysis, is a well-practiced tool in the chemical industry. The diverse applications have been enabled...
Currently Chief Technology Officer at Porton Pharmatech/J-Star Research, Inc. San Kiang is an SME in continuous processing API, continuous processing DP, particle engineering, pharmaceutical composite material, co-processing and pharmaceutical...
By Dr. San Kiang, J-Star Research / Porton The business goal of most CMC development is to reach FIH as fast as possible. However, before IND or Phase 1,...
By Dr. Simon Bates, Rigaku Americas Corp X-ray powder diffraction has been the gold standard for solid state pharmaceutical analysis for quite some time. However, when it comes to...
